THE EFFECTIVENESS OF BISOPROLOL IN PATIENTS WITH RHEUMATIC  HEART DISEASE WITH CHRONIC HEART FAILURE

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/7581

Full metadata record

DC Field	Value	Language
dc.contributor.author	Makhmudova M.S., Shukurdjanova S.M., Nuritdinova N.B.	-
dc.date.accessioned	2023-05-07T13:58:55Z	-
dc.date.available	2023-05-07T13:58:55Z	-
dc.date.issued	2023	-
dc.identifier.issn	2181-0974	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/7581	-
dc.description.abstract	After 3 months of treatment, the first group showed a decrease in proinflammatory cytokines TNF-alpha by 22.6%, interleukin-6 by 25.3%.In the second group, TNF-alpha decreased by 15.8%, interleukin-6 decreased by 18.1%.There were improvements in the clinical condition and quality of life, an increase in exercise tolerance. Bisoprolol is an effective drug for the treatment of rheumatic heart defects complicated by CHF II-III FC, having a beneficial effect on immunological parameters (reducing the amount of pro-inflammatory cytokines) and improving the quality of life.	en_US
dc.language.iso	en	en_US
dc.publisher	ИННОВАЦИОННЫЙ ПРОГРЕСС В ИССЛЕДОВАНИЯХ ВНУТРЕННЕЙ МЕДИЦИНЫ \| 2023 \| ЖУРНАЛ КАРДИОРЕСПИРАТОРНЫХ ИССЛЕДОВАНИЙ	en_US
dc.subject	bisoprolol, immunological parameters and quality of life, rheumatic heart defects, CHF	en_US
dc.title	THE EFFECTIVENESS OF BISOPROLOL IN PATIENTS WITH RHEUMATIC HEART DISEASE WITH CHRONIC HEART FAILURE	en_US
dc.type	Thesis	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
Tezis (2).pdf	THE EFFECTIVENESS OF BISOPROLOL IN PATIENTS WITH RHEUMATIC HEART DISEASE WITH CHRONIC HEART FAILURE	3.65 MB	Adobe PDF	View/Open

DSpace JSPUI